Schroeder C, et al. - Researchers focused on the relevance of microtubule-associated protein Tau (MAPT) in prostate cancer. They performed immunohistochemistry on a tissue microarray containing 17,747 prostate cancers, to determine MAPT expression. They found that normal prostate epithelial cells did not exhibit MAPT, whereas, MAPT was detectable in 1004 (8.2%) of 12,313 interpretable cancers. The factors that showed relation to MAPT expression were: advanced tumor stage, high Gleason grade, positive lymph nodes, and early biochemical recurrence. In multivariate analysis, MAPT displayed prognostic value that did not depend on established parameters. MAPT was identified as a moderate prognostic marker in prostate cancer. The rarity and heterogeneity of its expression were held responsible for a possibly limited clinical effect of MAPT.